+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Antidepressants Drugs Market by Drug Class, Indication, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5715760
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antidepressants Drugs Market grew from USD 20.71 billion in 2023 to USD 22.44 billion in 2024. It is expected to continue growing at a CAGR of 9.85%, reaching USD 39.99 billion by 2030.

The antidepressant drugs market encompasses a wide scope, primarily defined by medications designed to relieve symptoms of depression by altering chemical levels in the brain, such as serotonin and norepinephrine. The necessity of these drugs arises from the growing incidence of depression and anxiety disorders worldwide, driven by factors such as stress, lifestyle changes, and greater awareness and diagnosis of mental health issues. Applications extend beyond major depressive disorder, covering anxiety, OCD, PTSD, and other mood disorders. End-use segments include hospitals, psychiatric clinics, and individual patients, with a rising trend in telemedicine consultations boosting market reach.

Key growth factors in this market include increased mental health awareness, improved public healthcare policies, and the development of novel drug formulations with fewer side effects. Additionally, the aging global population presents opportunities for growth, as older adults often face depression-related challenges. The introduction of personalized medicine approaches and AI-driven mental health assessments are significant opportunities that could revolutionize treatment efficacy and patient adherence. Expanding awareness campaigns and integrating digital health tools into treatment plans are recommended strategies to capitalize on market opportunities.

However, market growth faces limitations from patent expirations of major drugs, leading to increased generic competition and pricing pressures. The slow pace of regulatory approvals and the high cost of novel drug development also present challenges, alongside societal stigma and the potential for drug misuse or dependency.

Innovative areas and research opportunities lie in developing fast-acting antidepressant treatments, exploring alternative therapies such as psychedelic compounds, and enhancing drug delivery systems. The market is dynamic, shaped by technological advancements and evolving consumer needs, demanding continuous adaptation. Stakeholders should focus on reducing side effects and improving therapeutic outcomes to maintain a competitive edge. Thus, engaging in strategic partnerships and collaborative research will be essential for sustained growth in this burgeoning field.

Understanding Market Dynamics in the Antidepressants Drugs Market

The Antidepressants Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing incidences of PTSD, OCD, and anxiety issues
    • Favorable government initiatives and campaigns for mental health problems
    • Rise in number of mental health institutions and professionals
  • Market Restraints
    • Associated side effects and cost of antidepressants drugs
  • Market Opportunities
    • Innovative solutions for the development of novel antidepressants drugs
    • Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
  • Market Challenges
    • Social stigma surrounding mental health treatments

Exploring Porter’s Five Forces for the Antidepressants Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Antidepressants Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antidepressants Drugs Market

External macro-environmental factors deeply influence the performance of the Antidepressants Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antidepressants Drugs Market

The Antidepressants Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antidepressants Drugs Market

The Antidepressants Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Antidepressants Drugs Market

The Antidepressants Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antidepressants Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Angelini Pharma S.p.a., Apotex Inc., AstraZeneca PLC, Biogen Inc., Bristol Myers Squibb Company, CAPLYTA by Intra-Cellular Therapies, Inc., Divi’s Laboratories Limited, Dr. Reddy’s Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, Eridanus Healthcare, H. Lundbeck A/S, Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Mallinckrodt PLC, Merck & Co., Inc., Midas Pharma GmbH, Neurocon Inc., Organon & Co., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Somacare, SteriMax Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Antidepressants Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Class
    • Monoamine Oxidase Inhibitors
    • Reuptake Inhibitors
    • Selective Serotonin Reuptake Inhibitors
    • Serotonin Antagonist
    • Serotonin-Norepinephrine Reuptake Inhibitors
    • Tricyclic Antidepressants
  • Indication
    • Anxiety Disorders
    • Attention Deficit Hyperactivity Disorder
    • Major Depressive Disorder
  • Route of Administration
    • Injectable
    • Oral
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of PTSD, OCD, and anxiety issues
5.1.1.2. Favorable government initiatives and campaigns for mental health problems
5.1.1.3. Rise in number of mental health institutions and professionals
5.1.2. Restraints
5.1.2.1. Associated side effects and cost of antidepressants drugs
5.1.3. Opportunities
5.1.3.1. Innovative solutions for the development of novel antidepressants drugs
5.1.3.2. Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
5.1.4. Challenges
5.1.4.1. Social stigma surrounding mental health treatments
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Antidepressants Drugs Market, by Drug Class
6.1. Introduction
6.2. Monoamine Oxidase Inhibitors
6.3. Reuptake Inhibitors
6.4. Selective Serotonin Reuptake Inhibitors
6.5. Serotonin Antagonist
6.6. Serotonin-Norepinephrine Reuptake Inhibitors
6.7. Tricyclic Antidepressants
7. Antidepressants Drugs Market, by Indication
7.1. Introduction
7.2. Anxiety Disorders
7.3. Attention Deficit Hyperactivity Disorder
7.4. Major Depressive Disorder
8. Antidepressants Drugs Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
9. Antidepressants Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Americas Antidepressants Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Antidepressants Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Antidepressants Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Alembic Pharma gets USFDA nod to market generic antidepressant drug
13.3.2. Acquisition of CinCor Pharma complete
13.3.3. Zydus gets USFDA nod to market generic medicine for treating depression
13.3.4. RA Capital backs another startup hunting for a better antidepressant
13.3.5. Autobahn raises funds for ABX-002 advancement to treat depression
13.3.6. Axsome Therapeutics Announces FDA Approval of AUVELITY, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
13.3.7. Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
13.3.8. Osmind scores $40M investment to aid in mental health research and treatment
13.3.9. Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck
13.3.10. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
13.3.11. Granules India gets USFDA approval for generic antidepressant drug
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTIDEPRESSANTS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTIDEPRESSANTS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIDEPRESSANTS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTIDEPRESSANTS DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MONOAMINE OXIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ATTENTION DEFICIT HYPERACTIVITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. CANADA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. MEXICO ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. CHINA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. INDIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. JAPAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. THAILAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 111. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. DENMARK ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. EGYPT ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. FINLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. FRANCE ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. ITALY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. NORWAY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. POLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. QATAR ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SPAIN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. TURKEY ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM ANTIDEPRESSANTS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. ANTIDEPRESSANTS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 194. ANTIDEPRESSANTS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Antidepressants Drugs Market, which are profiled in this report, include:
  • A. N. Pharmacia Laboratories Pvt. Ltd.
  • AbbVie Inc.
  • Alkermes PLC
  • Angelini Pharma S.p.a.
  • Apotex Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • CAPLYTA by Intra-Cellular Therapies, Inc.
  • Divi’s Laboratories Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Eridanus Healthcare
  • H. Lundbeck A/S
  • Jabs Biotech Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • La Renon Healthcare Pvt. Ltd.
  • Lupin Ltd.
  • Mallinckrodt PLC
  • Merck & Co., Inc.
  • Midas Pharma GmbH
  • Neurocon Inc.
  • Organon & Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis AG
  • Sanofi S.A.
  • Somacare
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Wellona Pharma

Methodology

Loading
LOADING...

Table Information